SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2004
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-31979 |
|
84-1460811 |
||
|
(State or Other |
|
(Commission |
|
(IRS Employer |
||
|
|
|
|
|
|
||
|
3200 Walnut Street, Boulder, Colorado |
|
|
|
80301 |
||
|
(Address of Principal Executive Offices) |
|
|
|
(Zip Code) |
||
|
|
|
|
|
|
||
|
Registrant’s telephone number, including area code: (303) 381-6600 |
||||||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
(Former Name or Former Address, if Changed Since Last Report) |
||||||
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On March 5, 2004, the Registrant issued a press release announcing that it had received notification from the U.S. Food & Drug Administration that its investigational new drug application had become effective for ARRY-142886, the full text of which is attached hereto as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
|
99.1 |
Press release dated March 5, 2004 entitled “Array BioPharma’s Anticancer Compound ARRY-142886 Cleared To Advance Into Human Clinical Trials” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARRAY BIOPHARMA INC. |
|
|
|
|
|
|
|
|
|
|
Date: March 8, 2004 |
By: |
/s/ Robert E. Conway |
|
|
|
Robert E. Conway |
|
|
|
Chief Executive Officer |
3
EXHIBIT INDEX
|
Exhibit No. |
|
|
|
|
|
|
|
99.1 |
|
Press release dated March 5, 2004 entitled “Array BioPharma’s Anticancer Compound ARRY-142886 Cleared To Advance Into Human Clinical Trials” |
4